Butyrate as a key postbiotic in the modulation of neuroinflammation: toward precision therapy in treatment-resistant depression and anxiety - a narrative review
Medical Science Pulse · 20.05.2026
DOI: 10.5604/01.3001.0055.7707 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Pulse, erschienen am 20.05.2026. Verfasst von Anna Joanna Tomaszewska und 9 weiteren Autor:innen.
Themen: Depression
Abstract (Originalsprache)
Background
The escalating global burden of Treatment-Resistant Depression (TRD) and comorbid anxiety necessitates a fundamental shift in psychiatric therapeutic strategies. Traditional monoaminergic hypotheses often fail to account for the systemic inflammatory nature of affective disorders. Recent evidence identifies chronic, low-grade neuroinflammation - driven by the Microbiota-Gut-Brain (MGB) axis - as a primary mediator of treatment failure and neuronal atrophy. Postbiotics, specifically the short-chain fatty acid (SCFA) butyrate, offer a stable, standardized, and bioavailable alternative to live probiotics.
Aim of the study: This review provides a comprehensive synthesis of the molecular mechanisms by which butyrate modulates neuroinflammatory pathways, stabilizes biological barriers, and acts as a potent epigenetic regulator to improve clinical outcomes in TRD.
Material and methods: A comprehensive narrative review of 49 high-impact studies published between 2010 and 2025 was conducted using PubMed, Web of Science, and Google Scholar.
Results
Preclinical data demonstrate that butyrate serves as a potent Histone Deacetylase (HDAC) inhibitor, promoting the expression of Brain-Derived Neurotrophic Factor (BDNF). Furthermore, butyrate mitigates "leaky gut" by upregulating Tight Junction (TJ) proteins (ZO-1, occludin) via the AMPK/Akt pathways and shifts microglial polarization from a pro-inflammatory (M1) to a neuroprotective (M2) phenotype through FFAR2 signaling.
Conclusions
Butyrate represents a cornerstone for the future of precision psychiatry. Integrating metabolic profiling (e.g., CRP, IL-6, and fecal SCFA levels) into clinical protocols may enable targeted postbiotic interventions in patients refractory to conventional pharmacotherapy.
Zitieren
APA
Tomaszewska, A. J., Kleszczewska, K. B., Jaremek, J., Pawelec, N., Lourenço, W., Skowron, W., Pietruszewska, H., Gruba, D., Matlakiewicz, M., & Zalewska, A. (2026). Butyrate as a key postbiotic in the modulation of neuroinflammation: toward precision therapy in treatment-resistant depression and anxiety - a narrative review. Medical Science Pulse. https://doi.org/10.5604/01.3001.0055.7707
Vancouver
Tomaszewska AJ, Kleszczewska KB, Jaremek J, Pawelec N, Lourenço W, Skowron W, et al. Butyrate as a key postbiotic in the modulation of neuroinflammation: toward precision therapy in treatment-resistant depression and anxiety - a narrative review. Medical Science Pulse. 2026. doi:10.5604/01.3001.0055.7707
BibTeX
@article{Tomaszewska2026,
author = {Tomaszewska, Anna Joanna and Kleszczewska, Katarzyna Barbara and Jaremek, Julia and Pawelec, Natalia and Lourenço, Wiktoria and Skowron, Wiktoria and Pietruszewska, Hanna and Gruba, Dorota and Matlakiewicz, Magdalena and Zalewska, Aleksandra},
title = {Butyrate as a key postbiotic in the modulation of neuroinflammation: toward precision therapy in treatment-resistant depression and anxiety - a narrative review},
journal = {Medical Science Pulse},
year = {2026},
doi = {10.5604/01.3001.0055.7707}
}
EUVIMED